Arbutus Biopharma (ABUS) vs Climb Bio (CLYM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Climb Bio (CLYM) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 549.1% versus a gain of 0.0%. Over five years, ABUS leads with a +5.1% price change compared with -33.6% for CLYM. Arbutus Biopharma is the larger company by market cap ($657.6 million vs $615.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | CLYM |
|---|---|---|
| Share price | $4.29 | $10.71 |
| Market cap | $657.55M | $615.14M |
| 1-day change | -4.24% | +0.28% |
| YTD return | -10.81% | +167.75% |
| 1-year return | 0.00% | +549.09% |
| 5-year return | +5.15% | -33.64% |
| P/E ratio (TTM) | 5.43 | — |
| EPS (TTM) | $0.79 | $-0.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $18.33 |
| 52-week low | $3.50 | $1.64 |
| Distance from 52-week high | -21.28% | -41.57% |
| Average volume | 4.65M | 1.39M |
| Shares outstanding | 153.28M | 57.44M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed ABUS by 549.1 percentage points over the past year.
ABUS vs CLYM FAQ
Which is bigger, Arbutus Biopharma or Climb Bio?
Arbutus Biopharma (ABUS) is larger, with a market capitalization of $657.55M compared with $615.14M for Climb Bio (CLYM).
Which stock has performed better over the past year, ABUS or CLYM?
CLYM returned +549.09% over the past 12 months, compared with 0.00% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Climb Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.